379 related articles for article (PubMed ID: 30536746)
41. Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial.
Kaku K; Isaka H; Sakatani T; Toyoshima J
Diabetes Obes Metab; 2019 Oct; 21(10):2284-2293. PubMed ID: 31173455
[TBL] [Abstract][Full Text] [Related]
42. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus.
Fonseca VA; Ferrannini E; Wilding JP; Wilpshaar W; Dhanjal P; Ball G; Klasen S
J Diabetes Complications; 2013; 27(3):268-73. PubMed ID: 23276620
[TBL] [Abstract][Full Text] [Related]
43. Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects.
Takase T; Nakamura A; Miyoshi H; Yamamoto C; Atsumi T
Endocr J; 2017 Mar; 64(3):363-367. PubMed ID: 27980239
[TBL] [Abstract][Full Text] [Related]
44. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
[TBL] [Abstract][Full Text] [Related]
45. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.
Yokono M; Takasu T; Hayashizaki Y; Mitsuoka K; Kihara R; Muramatsu Y; Miyoshi S; Tahara A; Kurosaki E; Li Q; Tomiyama H; Sasamata M; Shibasaki M; Uchiyama Y
Eur J Pharmacol; 2014 Mar; 727():66-74. PubMed ID: 24486393
[TBL] [Abstract][Full Text] [Related]
46. Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
Eur J Pharmacol; 2018 Jan; 818():545-553. PubMed ID: 29154936
[TBL] [Abstract][Full Text] [Related]
47. Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
Kashiwagi A; Sakatani T; Nakamura I; Akiyama N; Kazuta K; Ueyama E; Takahashi H; Kosakai Y
Endocr J; 2018 Jul; 65(7):693-705. PubMed ID: 29848902
[TBL] [Abstract][Full Text] [Related]
48. Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study.
Sasaki T; Sugawara M; Fukuda M
J Diabetes Investig; 2019 Jan; 10(1):108-117. PubMed ID: 29660782
[TBL] [Abstract][Full Text] [Related]
49. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.
Shin Y; Moon JH; Chin HJ; Ferrannini E; Lim S
Endocrinol Metab (Seoul); 2020 Jun; 35(2):329-338. PubMed ID: 32615717
[TBL] [Abstract][Full Text] [Related]
50. Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.
Matsuba I; Kawata T; Iemitsu K; Asakura T; Amemiya H; Ishikawa M; Ito S; Kaneshiro M; Kanamori A; Kubota A; Shinoda K; Takai M; Takuma T; Takihata M; Takeda H; Tanaka K; Matsuzawa Y; Machimura H; Minagawa F; Minami N; Mokubo A; Miyakawa M; Terauchi Y; Tanaka Y
J Diabetes Investig; 2020 Sep; 11(5):1248-1257. PubMed ID: 32149469
[TBL] [Abstract][Full Text] [Related]
51. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
[TBL] [Abstract][Full Text] [Related]
52. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.
Nishimura N; Kitade M; Noguchi R; Namisaki T; Moriya K; Takeda K; Okura Y; Aihara Y; Douhara A; Kawaratani H; Asada K; Yoshiji H
J Gastroenterol; 2016 Dec; 51(12):1141-1149. PubMed ID: 27025708
[TBL] [Abstract][Full Text] [Related]
53. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.
Ohta A; Kato H; Ishii S; Sasaki Y; Nakamura Y; Nakagawa T; Nagai Y; Tanaka Y
Expert Opin Pharmacother; 2017 Oct; 18(14):1433-1438. PubMed ID: 28770629
[TBL] [Abstract][Full Text] [Related]
54. Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
Diabetes Obes Metab; 2018 May; 20(5):1176-1185. PubMed ID: 29316236
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
Fukuoka S; Dohi K; Takeuchi T; Moriwaki K; Ishiyama M; Omori T; Fujimoto N; Ito M
Heart Vessels; 2020 Sep; 35(9):1218-1226. PubMed ID: 32270357
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study).
Koshizaka M; Ishikawa K; Ishikawa T; Kobayashi K; Takemoto M; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Tatsuno I; Terano T; Hashimoto N; Kuribayashi N; Uchida D; Yokote K;
BMJ Open; 2017 May; 7(5):e015766. PubMed ID: 28490565
[TBL] [Abstract][Full Text] [Related]
57. The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes.
Okura T; Fujioka Y; Nakamura R; Kitao S; Ito Y; Anno M; Matsumoto K; Shoji K; Matsuzawa K; Izawa S; Okura H; Ueta E; Kato M; Imamura T; Taniguchi SI; Yamamoto K
Sci Rep; 2022 Feb; 12(1):1896. PubMed ID: 35115614
[TBL] [Abstract][Full Text] [Related]
58. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
Kitazawa M; Katagiri T; Suzuki H; Matsunaga S; H Yamada M; Ikarashi T; Yamamoto M; Furukawa K; Iwanaga M; Hatta M; Fujihara K; Yamada T; Tanaka S; Sone H
Diabetes Obes Metab; 2021 Mar; 23(3):811-821. PubMed ID: 33416200
[TBL] [Abstract][Full Text] [Related]
59. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
Kadokura T; Zhang W; Krauwinkel W; Leeflang S; Keirns J; Taniuchi Y; Nakajo I; Smulders R
Clin Pharmacokinet; 2014 Nov; 53(11):975-88. PubMed ID: 25316572
[TBL] [Abstract][Full Text] [Related]
60. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Bolinder J; Ljunggren Ö; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
Diabetes Obes Metab; 2014 Feb; 16(2):159-69. PubMed ID: 23906445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
